Abstract:The stable activation of the WNT signaling effector beta-catenin (CTNNB1(ex3)) in ovarian granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life. Although loss of the tumor suppressor gene Pten alone rarely leads to GCTs, its disruption in granulosa cells that concomitantly express a dominant-stable CTNNB1 mutant accelerates tumor formation. Expression of mutant (oncogenic) KRASG12D in granulosa cells results in the arrest of proliferation, differentiation and apoptosis. In this study, we sought to determine if KRAS activation would retard or block the ovarian phenotype of mice expressing dominant-stable CTNNB1. Unexpectedly, transgenic mice bearing mutations of CTNNB1 and KRAS developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1;Pten mutant mice. GCT cells in these animals were characterized by increased rates of proliferation, decreased apoptosis and reduced expression of markers of granulosa cell differentiation relative to normal ovaries. Microarray and RT-PCR studies were performed comparing control ovaries, ovaries from mice expressing dominant-stable CTNNB1, and ovaries bearing early-stage tumors from mice with the CTNNB1 mutation and either Pten loss or KRAS activation. Results demonstrated that gene regulatory processes induced by CTNNB1 were mostly further enhanced by either KRAS activation or Pten loss, and that the latter mutations largely affected the expression of the same genes in remarkably similar patterns. Granulosa cells from the tumors proliferate in culture and retain expression of selected CTNNB1 target genes. In addition, concomitant activation of CTNNB1 and KRAS in Sertoli cells resulted in the development of granulosa cell tumors of the testis similar to those observed in the Ctnnb1;Pten mutant mice. Real time-PCR studies showed a partial overlap in gene regulatory processes associated with tumor development in the ovarian and testicular GCTs. Collectively, these results suggest that mutant stable CTNNB1 alters the granulosa cell genetic program and predisposes these cells to transformation whereby either KRAS activation or Pten loss induce GCT development from premalignant lesions via highly similar molecular mechanisms. Supported in part by NIH-HD-16229 and HD-07945 (J.S.R.) and the Canadian Institutes of Health Research (D.B.). (poster)

Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development

Mutually Exclusive Mutations Of The Pten And Ras Pathways In Skin Tumor Progression

Pten Loss Promotes Ras(Ha)-Mediated Papillomatogenesis Via Dual Up-Regulation of Akt Activity and Cell Cycle Deregulation but Malignant Conversion Proceeds Via Pten-Associated Pathways

Data from <i>Pten</i> Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

Pten Deficiency Activates Distinct Downstream Signaling Pathways in A Tissue-Specific Manner

Genetic Background Controls Tumor Development In Pten-Deficient Mice

Data from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Data from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Simultaneous Haploinsufficiency of Pten and Trp53 Tumor Suppressor Genes Accelerates Tumorigenesis in a Mouse Model of Prostate Cancer

Loss of TGF-β Signaling and PTEN Promotes Head and Neck Squamous Cell Carcinoma Through Cellular Senescence Evasion and Cancer-Related Inflammation

Crosstalk of LKB1‐regulated and PTEN‐regulated Signals in Liver Morphogenesis and Tumor Development in Mice

pRb Inactivation in Mammary Cells Reveals Common Mechanisms for Tumor Initiation and Progression in Divergent Epithelia

Tsc1 Loss Synergizes with Kras Activation in Lung Cancer Development in the Mouse and Confers Rapamycin Sensitivity

Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

Ras drives malignancy through stem cell crosstalk with the microenvironment

Cooperativity of Oncogenic K-Ras and Downregulated P16/ink4a in Human Pancreatic Tumorigenesis

Supplementary Tables 1-2 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.

Either Kras Activation or Pten Loss Similarly Enhance the Mutant CTNNB1-Induced Genetic Program to Promote Granulosa Cell Tumor Development in Ovary and Testis.